Sk Biopharmaceuticals Co Ltd (326030) — Cash Flow-to-Debt Ratio
Sk Biopharmaceuticals Co Ltd (326030) has a Cash Flow-to-Debt Ratio of 0.23x as of December 2025, meaning its operating cash flow of ₩87.00 Billion could theoretically repay 0% of its total liabilities (₩372.04 Billion) in one year. See how much free cash does Sk Biopharmaceuticals Co Ltd generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sk Biopharmaceuticals Co Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Sk Biopharmaceuticals Co Ltd across 10 annual periods. Also explore 326030 net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Sk Biopharmaceuticals Co Ltd (2016–2025)
Year-by-year debt coverage analysis for Sk Biopharmaceuticals Co Ltd. For market capitalisation and broader financial context, see market cap of Sk Biopharmaceuticals Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.47x | ₩176.33 Billion | ₩372.04 Billion | ▲ +131.2% |
| 2024 | 0.21x | ₩94.90 Billion | ₩462.83 Billion | ▲ +187.5% |
| 2023 | -0.23x | ₩-94.20 Billion | ₩402.22 Billion | ▲ +49.1% |
| 2022 | -0.46x | ₩-159.92 Billion | ₩347.68 Billion | ▲ +1.2% |
| 2021 | -0.47x | ₩-92.87 Billion | ₩199.46 Billion | ▲ +73.2% |
| 2020 | -1.74x | ₩-210.73 Billion | ₩121.17 Billion | ▼ -225.2% |
| 2019 | -0.53x | ₩-81.33 Billion | ₩152.10 Billion | ▲ +86.0% |
| 2018 | -3.83x | ₩-141.28 Billion | ₩36.91 Billion | ▼ -99.0% |
| 2017 | -1.92x | ₩-98.34 Billion | ₩51.12 Billion | ▼ -81.6% |
| 2016 | -1.06x | ₩-48.94 Billion | ₩46.21 Billion | — |